Company Glenmark Life Sciences Limited

Equities

GLS

INE03Q201024

Pharmaceuticals

End-of-day quote NSE India S.E. 03:30:00 21/06/2024 am IST 5-day change 1st Jan Change
829.8 INR -1.18% Intraday chart for Glenmark Life Sciences Limited -2.77% +26.28%

Business Summary

Glenmark Life Sciences Limited is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as anti-fungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of approximately 1198 KL.

Number of employees: 1,824

Sales per Business

INR in Million2022Weight2023Weight Delta
Generic
93.0 %
19,154 90.2 % 20,099 93.0 % +4.93%
CDMO
7.0 %
1,720 8.1 % 1,513 7.0 % -12.05%

Sales per region

INR in Million2022Weight2023Weight Delta
India
52.4 %
21,232 100.0 % 11,330 52.4 % -46.64%
International
47.6 %
-- 10,282 47.6 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 58 13/19/13
Director of Finance/CFO - 01/22/01
Compliance Officer - 23/21/23
Chief Tech/Sci/R&D Officer - 14/20/14
Director/Board Member - 12/20/12
General Counsel - 01/19/01
Human Resources Officer 49 11/18/11

Members of the board

Members of the board TitleAgeSince
Director/Board Member 66 30/20/30
Chief Executive Officer 58 13/19/13
Human Resources Officer 49 11/18/11
Director/Board Member 64 08/21/08
Director/Board Member - 12/20/12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 122,527,172 19,263,516 ( 15.72 %) 0 15.72 %

Shareholders

NameEquities%Valuation
Nirma Ltd.
75.00 %
91,896,285 75.00 % 919 M ₹
9,609,571 7.843 % 96 M ₹
Union Asset Management Co. Pvt Ltd.
0.8299 %
1,016,863 0.8299 % 10 M ₹
Old Bridge Asset Management Pvt Ltd.
0.1299 %
159,200 0.1299 % 2 M ₹
Nippon Life India Asset Management Ltd. (Invt Mgmt)
0.0142 %
17,374 0.0142 % 173 706 ₹
State Street Global Advisors Ltd.
0.0125 %
15,371 0.0125 % 153 680 ₹
Motilal Oswal Asset Management Co. Ltd.
0.008834 %
10,824 0.008834 % 108 219 ₹
SBI Funds Management Ltd.
0.007986 %
9,785 0.007986 % 97 831 ₹
HDFC Asset Management Co. Ltd. (Invt Mgmt)
0.004992 %
6,116 0.004992 % 61 148 ₹
ICICI Prudential Life Insurance Co. Ltd. (Invt Port)
0.001002 %
1,228 0.001002 % 12 278 ₹

Company contact information

Glenmark Life Sciences Ltd.

4th Floor, OIA House 470 Cardinal Gracious Road

400099, Mumbai

+91 22 6829 7979

http://www.glenmarklifesciences.com
address Glenmark Life Sciences Limited(GLS)

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
829.8 INR
Average target price
932.6 INR
Spread / Average Target
+12.40%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. GLS Stock
  4. Company Glenmark Life Sciences Limited